Skip to main content
. 2022 Sep 16;9:980841. doi: 10.3389/fmolb.2022.980841

FIGURE 4.

FIGURE 4

Independent validation of the five candidate miRNAs. (A). Expression validation of circulating miR-16, miR-17, miR-27a, miR-19b and miR-106a in an independent cohort including 80 BC patients and 30 controls by quantitative RT-PCR analysis. (B). Receiver operating characteristic (ROC) curves of miR-16, miR-17, miR-27a, miR-19b and miR-106a in the validation cohort. The values of AUC, 95% CI and p were indicated in the graphs. (C). Upregulation of miR-16, miR-17, miR-27a, miR-19b, and miR-106a in plasma samples from MMTV-PYMT mammary tumor mice (n = 7) than that in normal controls (n = 3).